Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Proton Therapy | 78 | 2024 | 1638 | 9.050 |
Why?
|
Craniospinal Irradiation | 13 | 2022 | 133 | 2.480 |
Why?
|
Brain Neoplasms | 37 | 2023 | 4993 | 2.290 |
Why?
|
Relative Biological Effectiveness | 21 | 2024 | 226 | 2.120 |
Why?
|
Radiotherapy, Intensity-Modulated | 20 | 2023 | 2168 | 1.930 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 28 | 2024 | 2452 | 1.770 |
Why?
|
Cranial Irradiation | 12 | 2023 | 322 | 1.720 |
Why?
|
Medulloblastoma | 13 | 2024 | 586 | 1.670 |
Why?
|
Cerebellar Neoplasms | 14 | 2024 | 486 | 1.670 |
Why?
|
Protons | 23 | 2024 | 483 | 1.640 |
Why?
|
Memantine | 7 | 2023 | 50 | 1.350 |
Why?
|
Organs at Risk | 12 | 2023 | 560 | 1.330 |
Why?
|
Chordoma | 5 | 2022 | 170 | 1.240 |
Why?
|
Radiotherapy Dosage | 37 | 2024 | 4003 | 1.230 |
Why?
|
Linear Energy Transfer | 15 | 2024 | 105 | 1.190 |
Why?
|
Hippocampus | 11 | 2022 | 976 | 1.150 |
Why?
|
Radiation Injuries | 19 | 2022 | 1472 | 1.140 |
Why?
|
Glioma | 9 | 2023 | 1988 | 1.110 |
Why?
|
Radiotherapy, Image-Guided | 4 | 2024 | 338 | 1.080 |
Why?
|
Monte Carlo Method | 15 | 2021 | 704 | 1.040 |
Why?
|
Chondrosarcoma | 4 | 2017 | 213 | 1.030 |
Why?
|
Photons | 12 | 2021 | 537 | 1.030 |
Why?
|
Cognition | 13 | 2023 | 982 | 0.930 |
Why?
|
Skull Base Neoplasms | 4 | 2018 | 339 | 0.930 |
Why?
|
Radiobiology | 3 | 2018 | 56 | 0.870 |
Why?
|
Heavy Ion Radiotherapy | 5 | 2022 | 28 | 0.810 |
Why?
|
Ependymoma | 6 | 2023 | 269 | 0.810 |
Why?
|
Craniopharyngioma | 3 | 2023 | 56 | 0.760 |
Why?
|
Cognition Disorders | 6 | 2020 | 774 | 0.730 |
Why?
|
Phantoms, Imaging | 5 | 2024 | 1330 | 0.720 |
Why?
|
Heart | 3 | 2016 | 1214 | 0.700 |
Why?
|
Child | 59 | 2024 | 30492 | 0.690 |
Why?
|
Pituitary Neoplasms | 3 | 2023 | 218 | 0.670 |
Why?
|
Memory Disorders | 2 | 2018 | 295 | 0.640 |
Why?
|
Glioblastoma | 4 | 2023 | 1781 | 0.640 |
Why?
|
Lymphopenia | 1 | 2021 | 211 | 0.630 |
Why?
|
Memory, Short-Term | 1 | 2019 | 161 | 0.600 |
Why?
|
Child, Preschool | 40 | 2024 | 16999 | 0.580 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 7 | 2018 | 269 | 0.580 |
Why?
|
Radiotherapy | 6 | 2020 | 1860 | 0.580 |
Why?
|
Neurons | 3 | 2018 | 2461 | 0.560 |
Why?
|
Prefrontal Cortex | 1 | 2018 | 215 | 0.550 |
Why?
|
Radiotherapy, Conformal | 4 | 2016 | 898 | 0.550 |
Why?
|
Humans | 121 | 2024 | 271884 | 0.540 |
Why?
|
Skull Neoplasms | 1 | 2016 | 68 | 0.540 |
Why?
|
Radiometry | 11 | 2024 | 1017 | 0.530 |
Why?
|
Neutrons | 1 | 2016 | 117 | 0.530 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2021 | 5566 | 0.520 |
Why?
|
Neuronal Plasticity | 1 | 2018 | 326 | 0.520 |
Why?
|
Elementary Particles | 1 | 2015 | 24 | 0.510 |
Why?
|
Models, Biological | 5 | 2020 | 3223 | 0.500 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2021 | 404 | 0.490 |
Why?
|
Cochlea | 3 | 2024 | 118 | 0.480 |
Why?
|
Re-Irradiation | 3 | 2022 | 166 | 0.470 |
Why?
|
Neurosurgical Procedures | 1 | 2019 | 634 | 0.460 |
Why?
|
Radiotherapy Setup Errors | 1 | 2014 | 85 | 0.460 |
Why?
|
Cancer Survivors | 5 | 2021 | 744 | 0.450 |
Why?
|
Intelligence | 3 | 2019 | 134 | 0.450 |
Why?
|
Long-Term Potentiation | 5 | 2018 | 180 | 0.440 |
Why?
|
Sarcoma, Ewing | 3 | 2024 | 426 | 0.430 |
Why?
|
Neoplasms | 10 | 2021 | 15915 | 0.430 |
Why?
|
DNA Damage | 2 | 2024 | 1989 | 0.430 |
Why?
|
Lung Neoplasms | 5 | 2021 | 12012 | 0.430 |
Why?
|
Spine | 2 | 2013 | 311 | 0.430 |
Why?
|
Hearing Loss | 3 | 2024 | 173 | 0.420 |
Why?
|
Fetus | 1 | 2016 | 674 | 0.420 |
Why?
|
Adolescent | 39 | 2024 | 32663 | 0.420 |
Why?
|
Male | 60 | 2024 | 128957 | 0.390 |
Why?
|
Cognitive Dysfunction | 3 | 2022 | 329 | 0.390 |
Why?
|
Dose-Response Relationship, Radiation | 8 | 2024 | 751 | 0.390 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 313 | 0.380 |
Why?
|
Positron-Emission Tomography | 2 | 2024 | 2198 | 0.380 |
Why?
|
Cell Survival | 6 | 2021 | 3074 | 0.370 |
Why?
|
Rhabdomyosarcoma, Alveolar | 3 | 2021 | 64 | 0.370 |
Why?
|
Organ Sparing Treatments | 4 | 2018 | 280 | 0.370 |
Why?
|
Age Factors | 8 | 2024 | 5520 | 0.360 |
Why?
|
Head and Neck Neoplasms | 8 | 2021 | 4137 | 0.350 |
Why?
|
Astrocytoma | 1 | 2012 | 335 | 0.350 |
Why?
|
Female | 57 | 2024 | 149143 | 0.340 |
Why?
|
Chemoradiotherapy | 3 | 2024 | 2029 | 0.340 |
Why?
|
Insurance, Health, Reimbursement | 2 | 2021 | 67 | 0.340 |
Why?
|
Rhabdomyosarcoma, Embryonal | 2 | 2021 | 76 | 0.330 |
Why?
|
Brain | 8 | 2023 | 4252 | 0.330 |
Why?
|
Thoracic Neoplasms | 3 | 2018 | 349 | 0.320 |
Why?
|
Rhabdomyosarcoma | 3 | 2019 | 343 | 0.320 |
Why?
|
Radiation Protection | 2 | 2022 | 204 | 0.310 |
Why?
|
Meningeal Neoplasms | 1 | 2012 | 473 | 0.310 |
Why?
|
Gamma Rays | 2 | 2020 | 241 | 0.310 |
Why?
|
Brain Stem | 3 | 2022 | 185 | 0.300 |
Why?
|
Lung | 2 | 2016 | 3294 | 0.300 |
Why?
|
Insurance Coverage | 2 | 2021 | 272 | 0.290 |
Why?
|
Linear Models | 4 | 2017 | 1100 | 0.290 |
Why?
|
Prospective Studies | 16 | 2024 | 13400 | 0.280 |
Why?
|
Rats | 10 | 2021 | 6638 | 0.280 |
Why?
|
Algorithms | 8 | 2020 | 3923 | 0.270 |
Why?
|
Adult | 28 | 2024 | 81857 | 0.270 |
Why?
|
Scattering, Radiation | 3 | 2018 | 334 | 0.270 |
Why?
|
Carcinoma, Small Cell | 1 | 2008 | 427 | 0.250 |
Why?
|
Spinal Neoplasms | 4 | 2021 | 666 | 0.250 |
Why?
|
Neuroblastoma | 2 | 2022 | 703 | 0.250 |
Why?
|
Infant | 19 | 2022 | 13931 | 0.250 |
Why?
|
Excitatory Amino Acid Antagonists | 4 | 2018 | 164 | 0.250 |
Why?
|
Rats, Sprague-Dawley | 5 | 2018 | 2255 | 0.240 |
Why?
|
Bone Neoplasms | 3 | 2024 | 2668 | 0.230 |
Why?
|
Methylphenidate | 2 | 2022 | 91 | 0.230 |
Why?
|
Intelligence Tests | 3 | 2022 | 89 | 0.230 |
Why?
|
Follow-Up Studies | 13 | 2024 | 15267 | 0.230 |
Why?
|
National Cancer Institute (U.S.) | 3 | 2018 | 218 | 0.220 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2022 | 102 | 0.220 |
Why?
|
Neoplasms, Second Primary | 3 | 2021 | 1388 | 0.220 |
Why?
|
Survivors | 4 | 2022 | 1025 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 9 | 2022 | 10365 | 0.220 |
Why?
|
Combined Modality Therapy | 10 | 2021 | 9044 | 0.210 |
Why?
|
Tyrosine | 2 | 2003 | 510 | 0.210 |
Why?
|
Cosmic Radiation | 1 | 2022 | 15 | 0.210 |
Why?
|
Cell Death | 3 | 2020 | 689 | 0.210 |
Why?
|
Retrospective Studies | 22 | 2024 | 39780 | 0.210 |
Why?
|
Receptors, Glutamate | 1 | 2002 | 25 | 0.210 |
Why?
|
Protein Kinase C | 2 | 2002 | 419 | 0.210 |
Why?
|
Cisplatin | 3 | 2024 | 2497 | 0.200 |
Why?
|
Prostatic Neoplasms | 5 | 2021 | 5996 | 0.200 |
Why?
|
Astronauts | 1 | 2022 | 58 | 0.200 |
Why?
|
Models, Statistical | 2 | 2020 | 1190 | 0.200 |
Why?
|
Survivorship | 1 | 2022 | 117 | 0.200 |
Why?
|
Insurance, Health | 2 | 2021 | 263 | 0.200 |
Why?
|
Antigens, Surface | 1 | 2002 | 311 | 0.190 |
Why?
|
Radiation Exposure | 1 | 2022 | 74 | 0.190 |
Why?
|
Receptors, AMPA | 1 | 2002 | 83 | 0.190 |
Why?
|
Quality of Life | 7 | 2023 | 4749 | 0.190 |
Why?
|
Optic Nerve Glioma | 1 | 2021 | 28 | 0.190 |
Why?
|
Treatment Outcome | 13 | 2024 | 33863 | 0.190 |
Why?
|
Helium | 2 | 2022 | 23 | 0.190 |
Why?
|
Electrons | 2 | 2022 | 187 | 0.180 |
Why?
|
Young Adult | 16 | 2024 | 22108 | 0.180 |
Why?
|
Scoliosis | 1 | 2022 | 148 | 0.180 |
Why?
|
Space Flight | 1 | 2022 | 129 | 0.180 |
Why?
|
Hypothyroidism | 1 | 2022 | 211 | 0.180 |
Why?
|
Transcription Factor RelA | 1 | 2020 | 185 | 0.180 |
Why?
|
X-Rays | 1 | 2020 | 153 | 0.170 |
Why?
|
Hospitals, High-Volume | 1 | 2020 | 77 | 0.170 |
Why?
|
Central Nervous System Neoplasms | 2 | 2015 | 550 | 0.170 |
Why?
|
Xerostomia | 1 | 2021 | 204 | 0.170 |
Why?
|
Time-to-Treatment | 2 | 2018 | 312 | 0.170 |
Why?
|
Synapses | 2 | 2018 | 556 | 0.170 |
Why?
|
Child Behavior Disorders | 1 | 2019 | 76 | 0.170 |
Why?
|
Encephalitis | 1 | 2020 | 153 | 0.170 |
Why?
|
Diffusion Tensor Imaging | 1 | 2021 | 295 | 0.160 |
Why?
|
DNA End-Joining Repair | 1 | 2019 | 92 | 0.160 |
Why?
|
Insurance Claim Review | 1 | 2018 | 74 | 0.160 |
Why?
|
Abnormalities, Radiation-Induced | 1 | 2018 | 6 | 0.160 |
Why?
|
Cancer Care Facilities | 2 | 2020 | 908 | 0.160 |
Why?
|
Homologous Recombination | 1 | 2019 | 187 | 0.160 |
Why?
|
Infratentorial Neoplasms | 1 | 2018 | 48 | 0.150 |
Why?
|
Disease-Free Survival | 8 | 2020 | 10259 | 0.150 |
Why?
|
Pituitary Gland | 1 | 2018 | 157 | 0.150 |
Why?
|
Beta Particles | 1 | 2017 | 9 | 0.150 |
Why?
|
Dendritic Spines | 1 | 2018 | 58 | 0.150 |
Why?
|
Brain Stem Neoplasms | 1 | 2019 | 102 | 0.150 |
Why?
|
Proportional Hazards Models | 4 | 2023 | 5118 | 0.150 |
Why?
|
In Vitro Techniques | 5 | 2007 | 1742 | 0.150 |
Why?
|
Alpha Particles | 1 | 2017 | 26 | 0.150 |
Why?
|
Social Class | 1 | 2019 | 322 | 0.150 |
Why?
|
Dementia | 1 | 2022 | 482 | 0.150 |
Why?
|
Behavior, Animal | 1 | 2020 | 754 | 0.140 |
Why?
|
Rhabdoid Tumor | 2 | 2014 | 111 | 0.140 |
Why?
|
Longitudinal Studies | 2 | 2019 | 2053 | 0.140 |
Why?
|
Genes, BRCA1 | 1 | 2019 | 398 | 0.140 |
Why?
|
Spinal Cord | 3 | 2015 | 724 | 0.140 |
Why?
|
Activities of Daily Living | 1 | 2019 | 559 | 0.140 |
Why?
|
Hypothalamus | 1 | 2018 | 276 | 0.130 |
Why?
|
Executive Function | 1 | 2017 | 149 | 0.130 |
Why?
|
Oxygen | 1 | 2020 | 800 | 0.130 |
Why?
|
Radiosurgery | 2 | 2018 | 1368 | 0.130 |
Why?
|
Middle Aged | 14 | 2023 | 90395 | 0.130 |
Why?
|
Congresses as Topic | 1 | 2017 | 296 | 0.130 |
Why?
|
Databases, Factual | 2 | 2020 | 2287 | 0.130 |
Why?
|
Radiation Tolerance | 4 | 2021 | 636 | 0.130 |
Why?
|
Teratoma | 2 | 2014 | 253 | 0.130 |
Why?
|
Pelvic Neoplasms | 2 | 2014 | 203 | 0.130 |
Why?
|
Aged | 11 | 2023 | 73471 | 0.130 |
Why?
|
Attention | 1 | 2017 | 286 | 0.130 |
Why?
|
Tumor Burden | 5 | 2021 | 2035 | 0.130 |
Why?
|
Radiation Oncology | 1 | 2020 | 558 | 0.130 |
Why?
|
Animals | 15 | 2022 | 62807 | 0.130 |
Why?
|
Prognosis | 7 | 2024 | 22537 | 0.120 |
Why?
|
Adaptation, Psychological | 1 | 2019 | 787 | 0.120 |
Why?
|
Nootropic Agents | 1 | 2014 | 32 | 0.120 |
Why?
|
Ethmoid Bone | 1 | 2014 | 13 | 0.120 |
Why?
|
Developmental Disabilities | 1 | 2019 | 689 | 0.120 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 1295 | 0.120 |
Why?
|
Health Services Accessibility | 1 | 2021 | 809 | 0.120 |
Why?
|
Memory | 1 | 2018 | 443 | 0.120 |
Why?
|
Disease Progression | 5 | 2022 | 6909 | 0.120 |
Why?
|
Learning | 1 | 2018 | 432 | 0.120 |
Why?
|
Computer Simulation | 3 | 2015 | 1572 | 0.120 |
Why?
|
Axonal Transport | 1 | 2014 | 40 | 0.120 |
Why?
|
Enzyme Activation | 2 | 2012 | 1832 | 0.110 |
Why?
|
Anesthesia, Intravenous | 1 | 2014 | 40 | 0.110 |
Why?
|
Carcinoma, Acinar Cell | 1 | 2014 | 87 | 0.110 |
Why?
|
Feasibility Studies | 3 | 2014 | 2349 | 0.110 |
Why?
|
Water | 1 | 2016 | 383 | 0.110 |
Why?
|
Radiation Dosage | 4 | 2020 | 1043 | 0.110 |
Why?
|
Parotid Neoplasms | 1 | 2014 | 152 | 0.110 |
Why?
|
Protein Tyrosine Phosphatases | 2 | 2012 | 193 | 0.110 |
Why?
|
Spinal Cord Neoplasms | 1 | 2014 | 159 | 0.110 |
Why?
|
Cohort Studies | 3 | 2019 | 9491 | 0.110 |
Why?
|
Antineoplastic Agents, Immunological | 1 | 2022 | 1335 | 0.110 |
Why?
|
Neoplasm, Residual | 1 | 2019 | 1741 | 0.110 |
Why?
|
Cell Line, Tumor | 5 | 2024 | 14875 | 0.100 |
Why?
|
Lens, Crystalline | 1 | 2013 | 163 | 0.100 |
Why?
|
Molecular Imaging | 1 | 2014 | 187 | 0.100 |
Why?
|
Software | 2 | 2019 | 1385 | 0.100 |
Why?
|
N-Methylaspartate | 1 | 2012 | 54 | 0.100 |
Why?
|
Receptors, GABA-A | 1 | 2012 | 83 | 0.100 |
Why?
|
Thyroid Gland | 1 | 2014 | 369 | 0.100 |
Why?
|
Uncertainty | 3 | 2019 | 327 | 0.100 |
Why?
|
Anesthesia | 1 | 2015 | 306 | 0.100 |
Why?
|
Survival Rate | 7 | 2020 | 12533 | 0.100 |
Why?
|
Incidence | 3 | 2021 | 5861 | 0.100 |
Why?
|
Treatment Failure | 3 | 2021 | 1432 | 0.100 |
Why?
|
Fractures, Compression | 1 | 2012 | 42 | 0.100 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2014 | 343 | 0.100 |
Why?
|
Cross-Linking Reagents | 2 | 2002 | 167 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 5 | 2021 | 6270 | 0.100 |
Why?
|
Ear | 1 | 2011 | 39 | 0.100 |
Why?
|
Electrophysiology | 2 | 2002 | 364 | 0.100 |
Why?
|
Caspase 3 | 1 | 2012 | 481 | 0.090 |
Why?
|
Spinal Cord Injuries | 1 | 2014 | 350 | 0.090 |
Why?
|
Neuropsychological Tests | 3 | 2022 | 1175 | 0.090 |
Why?
|
Carbon | 2 | 2022 | 164 | 0.090 |
Why?
|
Salivary Gland Neoplasms | 1 | 2015 | 499 | 0.090 |
Why?
|
Biological Transport | 1 | 2012 | 645 | 0.090 |
Why?
|
Desmoplastic Small Round Cell Tumor | 1 | 2011 | 88 | 0.090 |
Why?
|
Kidney | 2 | 2022 | 2265 | 0.090 |
Why?
|
Phosphorylation | 3 | 2012 | 4984 | 0.090 |
Why?
|
Social Adjustment | 2 | 2022 | 115 | 0.090 |
Why?
|
Verbal Learning | 2 | 2022 | 87 | 0.090 |
Why?
|
Spinal Fractures | 1 | 2012 | 140 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2021 | 2443 | 0.090 |
Why?
|
Risk Factors | 7 | 2021 | 18045 | 0.090 |
Why?
|
Radiography | 1 | 2014 | 1993 | 0.090 |
Why?
|
Aged, 80 and over | 5 | 2018 | 31042 | 0.090 |
Why?
|
Abdominal Neoplasms | 1 | 2011 | 249 | 0.080 |
Why?
|
Neutropenia | 1 | 2013 | 1001 | 0.080 |
Why?
|
Synaptic Transmission | 1 | 2012 | 476 | 0.080 |
Why?
|
Fatigue | 3 | 2022 | 1280 | 0.080 |
Why?
|
Skin Diseases | 1 | 2012 | 366 | 0.080 |
Why?
|
Time Factors | 5 | 2021 | 13130 | 0.080 |
Why?
|
Electrocardiography | 1 | 2014 | 1196 | 0.080 |
Why?
|
Heart Diseases | 1 | 2014 | 739 | 0.080 |
Why?
|
Calcium-Binding Proteins | 2 | 2020 | 557 | 0.070 |
Why?
|
Ifosfamide | 1 | 2008 | 357 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 1707 | 0.070 |
Why?
|
Psychomotor Performance | 1 | 2008 | 239 | 0.070 |
Why?
|
Pyramidal Cells | 1 | 2007 | 171 | 0.070 |
Why?
|
Speech | 1 | 2008 | 140 | 0.070 |
Why?
|
Antineoplastic Agents | 5 | 2024 | 14653 | 0.070 |
Why?
|
Etoposide | 1 | 2008 | 905 | 0.060 |
Why?
|
Audiometry, Pure-Tone | 2 | 2018 | 31 | 0.060 |
Why?
|
Regression Analysis | 2 | 2018 | 1588 | 0.060 |
Why?
|
Stem Cell Transplantation | 1 | 2012 | 1423 | 0.060 |
Why?
|
Hearing | 2 | 2018 | 64 | 0.060 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 4071 | 0.060 |
Why?
|
Nerve Net | 1 | 2007 | 272 | 0.060 |
Why?
|
Cell Line | 3 | 2021 | 5432 | 0.060 |
Why?
|
Apolipoprotein E4 | 1 | 2023 | 45 | 0.060 |
Why?
|
Pregnancy | 1 | 2016 | 8100 | 0.050 |
Why?
|
Apolipoproteins E | 1 | 2023 | 235 | 0.050 |
Why?
|
Moon | 1 | 2022 | 13 | 0.050 |
Why?
|
Ions | 1 | 2022 | 58 | 0.050 |
Why?
|
Pilot Projects | 2 | 2022 | 2864 | 0.050 |
Why?
|
Chymotrypsin | 1 | 2002 | 38 | 0.050 |
Why?
|
Cell Fractionation | 1 | 2002 | 78 | 0.050 |
Why?
|
Cerebrospinal Fluid | 1 | 2002 | 127 | 0.050 |
Why?
|
Neoplasm Grading | 2 | 2019 | 1827 | 0.050 |
Why?
|
Tooth Abnormalities | 1 | 2021 | 14 | 0.050 |
Why?
|
Infant, Newborn | 3 | 2021 | 8602 | 0.050 |
Why?
|
Okadaic Acid | 1 | 2001 | 32 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 4 | 2023 | 7929 | 0.050 |
Why?
|
Insurance Carriers | 1 | 2021 | 12 | 0.050 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2018 | 2270 | 0.050 |
Why?
|
Survival Analysis | 1 | 2012 | 9325 | 0.050 |
Why?
|
Graft vs Host Disease | 1 | 2012 | 2804 | 0.050 |
Why?
|
Parotid Gland | 1 | 2021 | 116 | 0.050 |
Why?
|
Excitatory Postsynaptic Potentials | 1 | 2002 | 254 | 0.050 |
Why?
|
Physics | 1 | 2021 | 44 | 0.050 |
Why?
|
Gliosis | 1 | 2020 | 44 | 0.050 |
Why?
|
Ethanol | 1 | 2003 | 269 | 0.050 |
Why?
|
Salivary Glands | 1 | 2021 | 140 | 0.050 |
Why?
|
NF-KappaB Inhibitor alpha | 1 | 2020 | 137 | 0.050 |
Why?
|
HMGB1 Protein | 1 | 2020 | 40 | 0.050 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2001 | 252 | 0.050 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2020 | 75 | 0.050 |
Why?
|
United States | 4 | 2018 | 16050 | 0.050 |
Why?
|
Biology | 1 | 2021 | 76 | 0.050 |
Why?
|
Heterozygote | 1 | 2023 | 1057 | 0.050 |
Why?
|
Peptide Hydrolases | 1 | 2002 | 264 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2008 | 4352 | 0.040 |
Why?
|
Chloride Channels | 1 | 2020 | 79 | 0.040 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2020 | 173 | 0.040 |
Why?
|
In Situ Nick-End Labeling | 1 | 2020 | 449 | 0.040 |
Why?
|
Neurogenesis | 1 | 2022 | 240 | 0.040 |
Why?
|
Cricetulus | 1 | 2020 | 215 | 0.040 |
Why?
|
Molecular Dynamics Simulation | 1 | 2020 | 140 | 0.040 |
Why?
|
Salvage Therapy | 2 | 2021 | 2119 | 0.040 |
Why?
|
Proctitis | 1 | 2019 | 19 | 0.040 |
Why?
|
Antiparkinson Agents | 1 | 2020 | 69 | 0.040 |
Why?
|
Blotting, Western | 2 | 2003 | 3646 | 0.040 |
Why?
|
Amino Acid Sequence | 3 | 2001 | 4635 | 0.040 |
Why?
|
Cyclophosphamide | 2 | 2021 | 3231 | 0.040 |
Why?
|
Bevacizumab | 2 | 2014 | 957 | 0.040 |
Why?
|
Physical Phenomena | 1 | 2018 | 19 | 0.040 |
Why?
|
Random Allocation | 1 | 2020 | 746 | 0.040 |
Why?
|
Rad51 Recombinase | 1 | 2019 | 125 | 0.040 |
Why?
|
Vision Disorders | 1 | 2021 | 241 | 0.040 |
Why?
|
src-Family Kinases | 1 | 2002 | 487 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2020 | 685 | 0.040 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 2903 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2018 | 2679 | 0.040 |
Why?
|
Urinary Incontinence | 1 | 2019 | 150 | 0.040 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 2429 | 0.040 |
Why?
|
Cell Membrane | 1 | 2002 | 900 | 0.040 |
Why?
|
Florida | 1 | 2018 | 115 | 0.040 |
Why?
|
Massachusetts | 1 | 2018 | 144 | 0.040 |
Why?
|
Rats, Long-Evans | 1 | 2018 | 111 | 0.040 |
Why?
|
Endocrine System Diseases | 1 | 2018 | 91 | 0.040 |
Why?
|
Tumor Hypoxia | 1 | 2017 | 24 | 0.040 |
Why?
|
Research Report | 1 | 2019 | 144 | 0.040 |
Why?
|
Microfilament Proteins | 1 | 2020 | 497 | 0.040 |
Why?
|
Income | 1 | 2018 | 232 | 0.040 |
Why?
|
Lymphatic Irradiation | 1 | 2018 | 139 | 0.040 |
Why?
|
Nephrectomy | 1 | 2022 | 808 | 0.040 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2021 | 609 | 0.040 |
Why?
|
Drug Synergism | 1 | 2001 | 1364 | 0.040 |
Why?
|
Multimodal Imaging | 1 | 2021 | 553 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2019 | 327 | 0.040 |
Why?
|
Enzyme Inhibitors | 2 | 2003 | 1966 | 0.040 |
Why?
|
Margins of Excision | 1 | 2018 | 314 | 0.030 |
Why?
|
Organ Size | 1 | 2018 | 727 | 0.030 |
Why?
|
Gene Silencing | 1 | 2019 | 832 | 0.030 |
Why?
|
Immunotherapy | 2 | 2022 | 3545 | 0.030 |
Why?
|
Necrosis | 1 | 2018 | 604 | 0.030 |
Why?
|
Visual Acuity | 1 | 2021 | 861 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2012 | 5690 | 0.030 |
Why?
|
Isotopes | 1 | 2016 | 36 | 0.030 |
Why?
|
Interdisciplinary Communication | 1 | 2017 | 276 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2014 | 7975 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 7790 | 0.030 |
Why?
|
Genotype | 1 | 2023 | 4265 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 2018 | 358 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 686 | 0.030 |
Why?
|
Cystectomy | 1 | 2019 | 632 | 0.030 |
Why?
|
Sample Size | 1 | 2016 | 215 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2020 | 1613 | 0.030 |
Why?
|
Risk | 1 | 2019 | 1950 | 0.030 |
Why?
|
Neuroimaging | 1 | 2018 | 404 | 0.030 |
Why?
|
Mucositis | 1 | 2015 | 150 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 16610 | 0.030 |
Why?
|
Indans | 1 | 2014 | 71 | 0.030 |
Why?
|
Sacrum | 1 | 2015 | 139 | 0.030 |
Why?
|
Prostatectomy | 1 | 2019 | 1006 | 0.030 |
Why?
|
Benzhydryl Compounds | 1 | 2014 | 87 | 0.030 |
Why?
|
Thoracic Vertebrae | 1 | 2015 | 201 | 0.030 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 220 | 0.030 |
Why?
|
Lumbar Vertebrae | 1 | 2015 | 249 | 0.030 |
Why?
|
Fibroblasts | 1 | 2020 | 1670 | 0.030 |
Why?
|
Aging | 1 | 2002 | 1578 | 0.030 |
Why?
|
Troponin I | 1 | 2014 | 131 | 0.030 |
Why?
|
Alternative Splicing | 1 | 1997 | 613 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 1997 | 522 | 0.030 |
Why?
|
Medicare | 1 | 2018 | 934 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2018 | 3539 | 0.030 |
Why?
|
Medical Records | 1 | 2013 | 447 | 0.030 |
Why?
|
DNA | 1 | 2020 | 3088 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2014 | 340 | 0.020 |
Why?
|
Histones | 1 | 2019 | 1514 | 0.020 |
Why?
|
Erythema | 1 | 2012 | 48 | 0.020 |
Why?
|
Esophagitis | 1 | 2013 | 210 | 0.020 |
Why?
|
Antibodies, Monoclonal, Humanized | 2 | 2014 | 3392 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2016 | 1262 | 0.020 |
Why?
|
Registries | 1 | 2019 | 2250 | 0.020 |
Why?
|
Vomiting | 1 | 2013 | 361 | 0.020 |
Why?
|
Deglutition Disorders | 1 | 2015 | 488 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 4507 | 0.020 |
Why?
|
Nausea | 1 | 2013 | 540 | 0.020 |
Why?
|
Vinblastine | 1 | 2011 | 462 | 0.020 |
Why?
|
Cerebral Arteries | 1 | 2011 | 100 | 0.020 |
Why?
|
Interferons | 1 | 2011 | 301 | 0.020 |
Why?
|
DNA Repair | 1 | 2018 | 1912 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3978 | 0.020 |
Why?
|
Erythrocyte Transfusion | 1 | 2011 | 211 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2015 | 940 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2018 | 5787 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 2469 | 0.020 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2011 | 366 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 7232 | 0.020 |
Why?
|
Receptor, ErbB-2 | 1 | 1999 | 2649 | 0.020 |
Why?
|
Dacarbazine | 1 | 2011 | 505 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 4886 | 0.020 |
Why?
|
Mice | 2 | 2020 | 36041 | 0.020 |
Why?
|
Piperidines | 1 | 2014 | 1091 | 0.020 |
Why?
|
Camptothecin | 1 | 2011 | 538 | 0.020 |
Why?
|
Weight Loss | 1 | 2013 | 639 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2018 | 4968 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2020 | 7300 | 0.020 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2012 | 592 | 0.020 |
Why?
|
2-Amino-5-phosphonovalerate | 1 | 2007 | 27 | 0.020 |
Why?
|
Propionates | 1 | 2007 | 79 | 0.020 |
Why?
|
Pain Measurement | 1 | 2012 | 1016 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 3853 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2014 | 1265 | 0.020 |
Why?
|
Hyperthermia, Induced | 1 | 2011 | 510 | 0.020 |
Why?
|
Texas | 1 | 2018 | 6435 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2018 | 3080 | 0.020 |
Why?
|
Skin | 1 | 2012 | 1284 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2011 | 872 | 0.020 |
Why?
|
Apoptosis | 1 | 2020 | 7837 | 0.020 |
Why?
|
Biphenyl Compounds | 1 | 2007 | 192 | 0.020 |
Why?
|
Electric Stimulation | 1 | 2007 | 492 | 0.020 |
Why?
|
Protein Transport | 1 | 2007 | 739 | 0.020 |
Why?
|
Peritoneal Neoplasms | 1 | 2011 | 856 | 0.020 |
Why?
|
Biopsy | 1 | 2012 | 3544 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2019 | 13993 | 0.010 |
Why?
|
Signal Transduction | 1 | 2002 | 12222 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1999 | 9099 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2007 | 2337 | 0.010 |
Why?
|
Surveys and Questionnaires | 1 | 2015 | 5928 | 0.010 |
Why?
|
Precipitin Tests | 1 | 2003 | 360 | 0.010 |
Why?
|
Rats, Inbred F344 | 1 | 2002 | 238 | 0.010 |
Why?
|
Pediatrics | 1 | 2011 | 1184 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1999 | 6781 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2007 | 5104 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 15924 | 0.010 |
Why?
|
Blotting, Northern | 1 | 1999 | 735 | 0.010 |
Why?
|
Gene Amplification | 1 | 1999 | 770 | 0.010 |
Why?
|
COS Cells | 1 | 1997 | 423 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2007 | 4199 | 0.010 |
Why?
|
Biomarkers, Tumor | 1 | 2014 | 10750 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 1999 | 16241 | 0.010 |
Why?
|
Cytoplasm | 1 | 1997 | 718 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2011 | 4809 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 1997 | 493 | 0.010 |
Why?
|
Sequence Deletion | 1 | 1997 | 915 | 0.010 |
Why?
|
Exons | 1 | 1997 | 1388 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 1999 | 5804 | 0.010 |
Why?
|
Transfection | 1 | 1997 | 3165 | 0.010 |
Why?
|
Cell Nucleus | 1 | 1997 | 1740 | 0.010 |
Why?
|
Genetic Vectors | 1 | 1997 | 1885 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 1997 | 3512 | 0.010 |
Why?
|
Base Sequence | 1 | 1997 | 5499 | 0.010 |
Why?
|
Phenotype | 1 | 1999 | 6515 | 0.000 |
Why?
|
Ovarian Neoplasms | 1 | 1999 | 4795 | 0.000 |
Why?
|